BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...a potential path forward. “We’re looking for partners,” he said. While Avalon is confident that Silarus Therapeutics Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...for lysosomal storage disorders; Iron Horse Therapeutics is targeting EPHA4 for amyotrophic lateral sclerosis (ALS); Silarus Therapeutics Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland RSV Corp., Rockville, Md. Sanofi (Euronext Paris:SAN; NYSE:SNY), Paris, France Silarus Therapeutics Inc....
BioCentury | May 21, 2016
Company News

Avalon launches cancer play PDI Therapeutics

...the collaboration -- celiac play Sitari Pharmaceuticals Inc. (La Jolla, Calif) and iron deficiency company Silarus Therapeutics Inc....
BioCentury | Jun 22, 2015
Finance

Build-to-buy basket

...first three start-ups that were announced in 2013 and 2014. Those include iron deficiency play Silarus...
BioCentury | Sep 29, 2014
Company News

Silarus Therapeutics Inc., Thyritope Biosciences Inc., GlaxoSmithKline hematology, endocrine/metabolic, autoimmune news

...Avalon Ventures and GlaxoSmithKline launched Silarus and Thyritope. Each company may receive up to $10 million...
...companies will be housed at Avalon's COI Pharmaceuticals incubator and funded on a quarterly basis. Silarus...
...hormone, which acts on the hepcidin pathway, regulates iron supply for red blood cell production. Silarus...
BioCentury | Sep 29, 2014
Finance

Avalon-GSK bet on familiarity, speed

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures' double launch of iron play Silarus Therapeutics Inc. and autoimmune company...
...know quickly with an inexpensive, highly validated test whether these drugs are working," he said. Silarus...
...suppresses hepcidin during stress to raise plasma iron levels, thus facilitating increased erythropoiesis. Cardon said Silarus...
BioCentury | Sep 23, 2014
Company News

Avalon, GSK launch two newcos

...Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched Silarus Therapeutics Inc. (San Diego, Calif.) and Thyritope Biosciences Inc...
...companies will be housed at Avalon's COI Pharmaceuticals incubator, and funded on a quarterly basis. Silarus...
...hormone, which acts on the hepcidin pathway, regulates iron supply for red blood cell production. Silarus...
Items per page:
1 - 7 of 7
BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...a potential path forward. “We’re looking for partners,” he said. While Avalon is confident that Silarus Therapeutics Inc....
BioCentury | Aug 17, 2017
Finance

Built to purpose

...for lysosomal storage disorders; Iron Horse Therapeutics is targeting EPHA4 for amyotrophic lateral sclerosis (ALS); Silarus Therapeutics Inc....
...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland RSV Corp., Rockville, Md. Sanofi (Euronext Paris:SAN; NYSE:SNY), Paris, France Silarus Therapeutics Inc....
BioCentury | May 21, 2016
Company News

Avalon launches cancer play PDI Therapeutics

...the collaboration -- celiac play Sitari Pharmaceuticals Inc. (La Jolla, Calif) and iron deficiency company Silarus Therapeutics Inc....
BioCentury | Jun 22, 2015
Finance

Build-to-buy basket

...first three start-ups that were announced in 2013 and 2014. Those include iron deficiency play Silarus...
BioCentury | Sep 29, 2014
Company News

Silarus Therapeutics Inc., Thyritope Biosciences Inc., GlaxoSmithKline hematology, endocrine/metabolic, autoimmune news

...Avalon Ventures and GlaxoSmithKline launched Silarus and Thyritope. Each company may receive up to $10 million...
...companies will be housed at Avalon's COI Pharmaceuticals incubator and funded on a quarterly basis. Silarus...
...hormone, which acts on the hepcidin pathway, regulates iron supply for red blood cell production. Silarus...
BioCentury | Sep 29, 2014
Finance

Avalon-GSK bet on familiarity, speed

...GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures' double launch of iron play Silarus Therapeutics Inc. and autoimmune company...
...know quickly with an inexpensive, highly validated test whether these drugs are working," he said. Silarus...
...suppresses hepcidin during stress to raise plasma iron levels, thus facilitating increased erythropoiesis. Cardon said Silarus...
BioCentury | Sep 23, 2014
Company News

Avalon, GSK launch two newcos

...Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) launched Silarus Therapeutics Inc. (San Diego, Calif.) and Thyritope Biosciences Inc...
...companies will be housed at Avalon's COI Pharmaceuticals incubator, and funded on a quarterly basis. Silarus...
...hormone, which acts on the hepcidin pathway, regulates iron supply for red blood cell production. Silarus...
Items per page:
1 - 7 of 7